Gilead Sciences has made another foray into the natural killer (NK) cell category, paying $300 million upfront to access Dragonfly Therapeutics' TriNKET platform to find therapies for cance
The FDA has declined to approve two more cancer therapies developed by drugmakers based in China, in what may be further evidence of a tough line taken by the regulator for drugs tested out
Compared to a ‘critical organ’ that had been largely ignored, companies working to develop microbiome-based therapies believe there is untapped potential in the area.
Nektar has said it will cut 70% of its workforce in the wake of the comprehensive failure in trials of its immuno-oncology candidate bempegaldesleukin, which was discontinued last week.
Shares in Nkarta more than doubled yesterday on the results of early-stage clinical that suggested it could be on to a winner with its natural kill (NK) cell therapy platform.
